China currently runs more clinical trials than Europe and the US combined,leading the way in the development of CAR-T and TCR therapies. Boasting one of the largest economies in the world, commercial success within this market provides a signifcant opportunity for the global distribution of CAR-TCR Therapies.
As the race to globalise CAR-TCR Therapies continues, the CAR-TCR Summit Asia explores the next generation candidates that have improved efficacy in solid tumor indications such as gastric and colorectal cancers.
Join experts from Fosun Kite, JW Therapeutics, Legend Biotech, GSK, UnicarTherapy and many more to understand how we can effectively manipulate the immunosuppressive tumor microenvironment to ensure effective trafcking and homing of CAR-TCR cells in solid tumor indications.
Explore novel updates on the hotly anticipated work taking place to progress allogeneic cell therapies for improved commercial returns.Streamline your manufacturing and logistics supply chain to ensure effective global distribution of your CAR-TCR therapy product.
Join us and over 100 of the world’s leading experts as we work to deliver safe, effective and commercially viable global distribution of novel and innovative CAR-TCR products.